← All compounds

LL-37

Waiting for restock
5mg vial
A$ 107Rp 1.200.000
Bulk buy pricing
3–5 vials
A$ 98
Save ~9%
6–9 vials
A$ 93
Save ~13%
10+ vials
A$ 85
Save ~22%

An endogenous antimicrobial peptide produced by the body's immune cells and epithelial surfaces. Studied for broad antimicrobial action, modulation of inflammatory signalling, and support for wound healing and skin integrity.

Compound overview

What it is

LL-37 is the only human member of the cathelicidin antimicrobial peptide family. It is secreted by neutrophils, macrophages, mast cells, and epithelial cells at barrier surfaces — skin, gut, lung. It kills bacteria directly by disrupting cell membranes, exhibits antiviral activity against enveloped viruses, and acts as an immunomodulator — activating innate immune signalling, promoting wound healing, and modulating inflammatory responses through TLR4 signalling. It also stimulates angiogenesis and keratinocyte migration to support wound closure.

Antimicrobial defence at epithelial surfaces improves. Wound healing accelerates through keratinocyte migration and angiogenesis. Biofilm-forming bacteria (relevant in chronic wounds and chronic sinusitis) are disrupted. Inflammatory signalling is modulated — LL-37 can both stimulate an initial immune response and then dampen excessive inflammation. Skin barrier integrity and healing improve.

Studied outcomes
  • Broad-spectrum antimicrobial activity against gram-positive and gram-negative bacteria, fungi, and enveloped viruses
  • Accelerated wound healing via keratinocyte migration and angiogenesis in preclinical studies
  • Disruption of biofilm formation in chronic bacterial colonisation models
  • Modulation of TLR4 signalling and inflammatory cascades
  • Antiviral activity against influenza, HIV, and RSV in cell studies
Suitability

Who it's for

  • Recurrent or chronic infections where standard antibiotic approaches have not resolved the issue
  • Wound healing — chronic or difficult wounds
  • Skin barrier conditions — eczema, recurrent infections of the skin
  • Adjunct to immune restoration protocols in clients with deficient innate immunity
Who should avoid it
  • Pregnancy (insufficient data)
  • Those with psoriasis — LL-37 overexpression is implicated in psoriasis pathogenesis; use may worsen condition
  • Active autoimmune skin conditions — immunomodulatory action may not be predictable
Dosing guidance

Protocol guidance

Dose
0.5–1.0mg per day
Frequency
Once daily
Cycle length
4–8 weeks
Route
Subcutaneous injection; topical administration studied for wound healing
Timing
No strict timing
Safety

Contraindications & cautions

  • Psoriasis history is a contraindication — LL-37 is an endogenous trigger in psoriatic plaques
  • High-dose administration can have pro-inflammatory effects in some tissue contexts — stay within research dosing
  • Human clinical data primarily from innate immunity and wound healing research
Stacking

Pairs well with

Complete immune restoration — innate defence (LL-37) + adaptive T-cell function (Thymosin Alpha-1)

BPC-157 connective tissue repair + LL-37 wound closure and antimicrobial action

Antioxidant and immune support alongside LL-37 innate immune action

Evidence base

Research

Zanetti (2004) — LL-37 cathelicidin review ↗Doss et al. (2010) — LL-37 multifunctional roles review ↗

Not medical advice. Not a substitute for medical care. Consult your licensed practitioner before beginning any protocol. Peptides are sold for research purposes only and are suitable for adults aged 18 years and over.